News

Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1
ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...
STAT5d
Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug
A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...
Fierce Pharma1d
Gilead reprimanded after PMCPA finds conference Wi-Fi sponsorship broke advertising rules
Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. The PMCPA ruled the ...
allAfrica.com on MSN4d
Game-changer: 6-monthly anti-HIV jab could end Aids in South Africa by 2032
A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 - but only if between two and ...
pharmaphorum1d
FDA sets June date for Gilead's twice-yearly HIV PrEP
Gilead Sciences' already dominant position in HIV ... review of the injectable formulation of HIV-1 capsid inhibitor lenacapavir, which also has breakthrough status, and is due to deliver a ...
AllAfrica.com4d
South Africa: The 6-Monthly Anti-HIV Jab Could End Aids in South Africa by 2032
TB and Malaria announced in December they had signed a product supply deal with lenacapavir's manufacturer, Gilead Sciences, to buy enough of the drug for two million people over the next three ...
Mail & Guardian6d
The six-monthly anti-HIV jab could end Aids in SA by 2032
TB and Malaria announced in December they had signed a product supply deal with lenacapavir’s manufacturer, Gilead Sciences, to buy enough of the drug for two million people over the next three ...